Detection of single-chain precursor residues in insulin glargine by ELISA

doi:10.19803/j.1672-8629.20230404

Abstract

Abstract: Objective To establish an enzyme-linked immunoassay for the detection of single-chain precursor residues in insulin glargine so as to recommend a new method for quality control and safety evaluation of insulin glargine. Methods An enzyme-linked immunoassay based on double antibody sandwich was established by using proinsulin glargine as the standard. The repeatability, accuracy, scope and precision of the method were verified, and nine batches of insulin glargine drug substances were tested using this method. Results Four-parameter curve fitting was performed using the proinsulin glargine standard at concentrations ranging from 0.156 to 10.00 ng·mL^-1, and the correlation coefficient of the curve exceeded 0.99. This method was highly accurate and repeatable. Three batches of insulin glargine drug substances were repeatedly detected. The average recovery ranged from 104% to 113%, and the RSD% was less than 10%, suggesting the good precision of this method. The single-chain precursor residues in all the nine batches were less than 1 ng·mg^-1. Conclusion The enzyme-linked immunoassay established in this study can be used for quality control and safety evaluation of single-chain precursor residues in insulin glargine and other recombinant human insulin analogues.

Key words: enzyme linked immunosorbent assay(ELISA), insulin glargine, single-chain precursor, C peptide, quality control, method validation, safety, recovery rate

CLC Number:

R917

ZHANG Xiaoming, LYU Ping, HU Xinyue, DING Xiaoli, LI Jing, LIANG Chenggang. Detection of single-chain precursor residues in insulin glargine by ELISA[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 290-294.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.20230404

https://www.zgywjj.com/EN/Y2024/V21/I3/290

References

[1] SEBASTIAN SA, CO EL, MEHENDALE M, et al.Insulin analogs in the treatment of type II diabetes and future perspectives[J]. Dis Mon, 2023, 69(3): 1-11.
[2] KABRA UD, JASTROCH M.Mitochondrial dynamics and insulin secretion[J]. Int J Mol Sci, 2023, 24(18): 2-19.
[3] VARGAS-URICOECHEA H.Current state and principles of basal insulin therapy in type 2 diabetes[J]. J Clin Med Res, 2022, 14(1): 8-21.
[4] LE TKC, DAO XD, NGUYEN DV, et al.Insulin signaling and its application[J]. Front Endocrinol[J], 2023, 8(14): 1-9.
[5] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China, Volume III(中华人民共和国药典三部)[M]. Beijing: China Medical Science Press, 2020: 466-472.
[6] USP. Usp2022-NF[S/OL].(2022-12-01). https://online.uspnf.com/uspnf/document/1_GUID-1FB2BBF9-9095-4966-BB9B-4B549843ED43_5_en-US?source=Activity.
[7] EDQM. European Pharmacopoeia 11.4[S]. Strasbourg Cedex: European Directorate for the Quality of Medicines & HealthCare, 2022: 3088-3090.
[8] HAZRA P, SREENIVAS S, VENKATESAN K, et al.A novel peptide design aids in the expression and its simplified process of manufacturing of Insulin Glargine in Pichia pastoris[J]. Appl Microbiol Biotechnol, 2021, 105(8): 3061-3074.
[9] LENG C, LI Q, WU F, et al.Detection of the single-chain precursor in the production and purification process of recombinant human insulin[J]. Monoclon Antib Immunodiagn Immunother, 2013, 32(4): 255-261.
[10] DING XL, G YP, ZHANG H, et al. Determination of insulin precursor in recombinant human insulin by RP-HPLC[J]. Chinese Journal of New Drugs(中国新药杂志), 2015, 24(15): 1707-1710.
[11] SIEW YY, ZHANG W.Downstream processing of recombinant human insulin and its analogues production from E. coli inclusion bodies[J]. Bioresour Bioprocess, 2021, 8(1): 65.
[12] XU KZ, LYU P, DING XL, et al.Detection of tetracycline residue in insulin preparation of lispro[J]. Chinese Journal of New Drugs(中国新药杂志), 2022, 31(19): 1883-1887.
[13] CHANCE RE, FRANK BH.Research, development, production, and safety of biosynthetic human insulin[J]. Diabetes Care, 1993, 16(Suppl 3): 133-142.
[14] COWLEY DJ, MACKIN RB.Expression, purification and characterization of recombinant human proinsulin[J]. FEBS Lett, 1997, 402(2-3): 124-130.
[15] BAESHEN NA, BAESHEN MN, SHEIKH A, et al.Cell factories for insulin production[J]. Microb Cell Fact, 2014, 13(1): 141-150.
[16] REDWAN M, MATAR SM, EL-AZIZ GA, et al.Synthesis of the human insulin gene: protein expression, scaling up and bioactivity[J]. Prep Biochem Biotechnol, 2008, 38(1): 24-39.
[17] KJELDSEN T.Yeast secretory expression of insulin precursors[J]. Appl Microbiol Biotechnol, 2000, 54(3): 277-286.
[18] WEISS MA.Diabetes mellitus due to the toxic misfolding of proinsulin variants[J]. FEBS Lett, 2013, 587(13): 1942-1950.
[19] PFÜTZNER A, KANN PH, PFüTZNER AH, et al. Intact and total proinsulin: new aspects for diagnosis and treatment of type 2 diabetes mellitus and insulin resistance[J]. Clin Lab, 2004, 50(9-10): 567-573.
[20] GALLOWAY JA, HOOPER SA, SPRADLIN CT, et al.Biosynthetic human proinsulin: review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience[J]. Diabetes Care, 1992, 15(5): 666-692.
[21] YUDKIN JS.Circulating proinsulin-like molecules[J]. J Diabetes Complications, 1993, 7(2): 113-123.
[22] LIANG CG, LI J, ZHANG H, et al.Considerations on research of national standards for recombinant hormones[J]. Chin J Pharm Anal(药物分析杂志), 2022, 42(1): 3-12.